Fractyl Health, Inc. is a biotechnology company focused on developing innovative therapies for metabolic diseases, particularly type 2 diabetes and obesity. The company aims to transform the treatment landscape through its proprietary approach, which combines advanced medical technologies with a deep understanding of metabolic health. By addressing underlying issues related to metabolism, Fractyl seeks to improve patient outcomes and enhance overall health. Through its research and development efforts, the company is dedicated to delivering scalable and effective solutions that can significantly impact the lives of individuals struggling with these chronic conditions. Read More
Participants who lost 24% total body weight (>50 lbs.) on GLP-1 drugs maintained stable weight 6 months after GLP-1 discontinuation and single Revita treatment
BURLINGTON, Mass., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the Company or Fractyl), a metabolic therapeutics company focused on pattern-breaking approaches that treat root causes of obesity and type 2 diabetes (T2D), today announced that Harith Rajagopalan, M.D., Ph.D., Co-Founder and Chief Executive Officer of the Company, will be participating in a fireside chat at the 8th Annual Evercore Healthcare Conference, being held December 2-4, 2025, in Coral Gables, FL.
Positive randomized 3-month REMAIN-1 Midpoint Cohort data showed single Revita procedure maintained weight loss after GLP-1 discontinuation; 6-month data expected in Q1 2026
BURLINGTON, Mass., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the Company), a metabolic therapeutics company focused on pattern-breaking approaches to treat the root causes of obesity and type 2 diabetes (T2D), today announced it will report financial results for the third quarter 2025 and provide business updates on Wednesday, November 12, 2025, at 4:30 p.m. ET.
RJVA-002 achieved ~30% weight loss at five weeks in a translational obesity model; weight loss not yet plateauedPreclinical results show that a single point-in-time treatment with RJVA-002 has the potential to achieve significant weight loss that can match or exceed best-in-class chronic drug therapy
A new class of Maga Stocks is heating up, blending health, wellness, tech, and critical minerals into some of the most compelling stories on Wall Street today. Here’s why investors are watching:
Gainers Indaptus Therapeutics (NASDAQ: INDP) stock moved upwards by 108.1% to $6.83 during Friday's regular session. The market value of their outstanding shares is at $3.6 million.
Gainers bioAffinity Technologies (NASDAQ: BIAF) stock increased by 71.8% to $5.86 during Friday's pre-market session. The company's market cap stands at $4.5 million.
Pilot study met key 3-month efficacy endpoint with strong statistical significance (p=0.014); Revita-treated patients lost an additional 2.5% total body weight after stopping GLP-1 drugs vs. 10% regain in sham-treated patients
Fractyl Health reports Q2 2025 net loss of $27.9M, missing EPS estimates. No revenue, but clinical progress in Revita and Rejuva programs. Stock dips amid investor concerns.
